Expert Clinical Network Insights Hemophilia Medication insights: marstacimab-hncq (Hympavzi) The U.S. Food and Drug Administration (FDA) approved marstacimab-hncq (Hympavzi) in October 2024 for...

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care Click on the poster image to view the full-size version. Validation of Long-term Savings from a...

Read more about Prime’s leading research and insights Real-World 2-Year Clinical Outcomes Following Initiation of Glucagon-Like Peptide-1 Agonists to Treat Obesity Without Diabetes Among a...

cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care  Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...

HighTouchRx® Insert Link Learn more about biosimilars As part of our comprehensive drug management strategy, we actively promote the evidence-based use of FDA-approved biosimilars and other...

Jan. 28, 2025 – hydrochlorothiazide (Inzirqo) 505(b)(2) NDA approval; Standard Review; first oral suspension formulation of hydrochlorothiazide; previously available oral solutions are no longer...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Durvalumab (Imfinzi) AstraZeneca; MedImmune IV Programmed...

May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents and children. This Clinical Insights white paper...

January 31, 2025 All brand names are property of their respective owners. Dec. 13, 2024 – cosibelimab-ipdl (Unloxcyt) Checkpoint’s Unloxcyt has received FDA approval for the treatment of adults...

PUBLICATIONS FDA Decisions Expected: February 2025 Drug pipeline for February 2025 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Proposed indications Non-muscle invasive bladder cancer (NMIBC) FDA approval timeline March to May 2026 Standard Review Place in therapy Sasanlimab is a humanized immunoglobulin G4 (IgG4)...

publications High-Cost Therapy Profile: April 2025 Deramiocel Intravenous (IV) | Nippon Shinyaku Co., Ltd./Capricor Therapeutics, Inc. Clinical deep dive Disease state overview DMD is a severe,...

May 15, 2025 Oncology-Gene therapy Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Bifikafusp Alfa; Onfekafusp...

Abbvie is seeking Accelerated Approval of Teliso-V in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in Las Vegas.

Nov. 29, 2024 - ustekinumab-kfce (Yesintek) The FDA has approved Biocon’s Yesintek as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is indicated for all...

13th annual report the preeminent source for medical benefit drug trend

More than 300 pharma representatives attended this annual gathering to learn more about what Prime/MRx has to offer

Managed Healthcare Executive

Reimagine your pharmacy benefit partner Get expert insights Go Somewhere Save, Simplify, Support™ Biologic drugs are transforming lives for the better, yet often at a substantial cost. Biosimilars,...